<DOC>
	<DOCNO>NCT01900041</DOCNO>
	<brief_summary>Pantovigar - high effective product design primarily treatment diffuse hair loss woman well treatment damage hair , combine therapy successfully apply type alopecia . The purpose study evaluate efficacy tolerability combination therapy Pantovigar plus 2 % minoxidil vs 2 % minoxidil . To collect tolerability data combine treatment Pantovigar plus 2 % Minoxidil course therapy .</brief_summary>
	<brief_title>A Study Evaluate Superiority , Efficacy Tolerability Combination Pantovigar With 2 % Minoxidil vs 2 % Minoxidil Women With Female Pattern Hair Loss</brief_title>
	<detailed_description />
	<mesh_term>Alopecia</mesh_term>
	<mesh_term>Alopecia Areata</mesh_term>
	<mesh_term>Minoxidil</mesh_term>
	<criteria>Female patient complaint hair loss and/or hair density reduction 3 month . More 15 % telogen frontoparietal hair show phototrichogram . Symptomatic diffuse alopecia ( screen iron thyroid function , thyroid stimulating hormon , triiodothyrine , ferritin , total ironbinding capacity ) Active history systemic autoimmune disease , e.g . lupus erythematodes etc . Hyperandrogenic alopecia ( polycystic ovary syndrome , adrenogenital syndrome , tumor androgenic activity ) ( testosterone , prolactin hormone , androstenedione , dehydroepiandrosterone ) Initiation termination hormone therapy within 6 month prior enter study Hormone therapy androgenic action , e.g . norethisterone etc . Pregnancy lactation within 6 month prior enter study Alopecia areata Scarring alopecia Treatment hair promote agent within 3 month prior enter study Known hair loss drug intake Concomitant use drug cause hair loss ( e.g . aromatase inhibitor , thyreostatics , cytostatics , etc , )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>